1. Home
  2. YSG vs SGHT Comparison

YSG vs SGHT Comparison

Compare YSG & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$3.40

Market Cap

292.7M

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$8.14

Market Cap

309.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
SGHT
Founded
2016
2011
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
292.7M
309.6M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
YSG
SGHT
Price
$3.40
$8.14
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
82.4K
229.7K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.16
EPS
N/A
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
$23.08
$11.67
Revenue Next Year
$9.45
$10.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$3.19
52 Week High
$10.59
$9.24

Technical Indicators

Market Signals
Indicator
YSG
SGHT
Relative Strength Index (RSI) 51.90 84.52
Support Level $3.25 $8.00
Resistance Level $3.49 $8.93
Average True Range (ATR) 0.22 0.52
MACD 0.00 0.30
Stochastic Oscillator 77.78 91.60

Price Performance

Historical Comparison
YSG
SGHT

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: